All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE- COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F23%3A00079141" target="_blank" >RIV/65269705:_____/23:00079141 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14110/23:00132482

  • Result on the web

    <a href="https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.47.2300187" target="_blank" >https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.47.2300187</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.2807/1560-7917.ES.2023.28.47.2300187" target="_blank" >10.2807/1560-7917.ES.2023.28.47.2300187</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE- COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

  • Original language description

    Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients &gt;= 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received &gt;= 14 days before symptom onset (stratifying first booster into received &lt; 150 and &gt;= 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received &gt;= 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset &lt; 120 days after first booster dose.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30303 - Infectious Diseases

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2023

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Eurosurveillance

  • ISSN

    1025-496X

  • e-ISSN

    1560-7917

  • Volume of the periodical

    28

  • Issue of the periodical within the volume

    47

  • Country of publishing house

    SE - SWEDEN

  • Number of pages

    17

  • Pages from-to

    2300187

  • UT code for WoS article

    001117609400001

  • EID of the result in the Scopus database

    2-s2.0-85177865991